John Karan, MD
Neurology · Antioch, CANPI 1720007545
Payments from drug & device makers
Across 94 payments — averaging $39.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- Neurocrine Biosciences, Inc.$320
- AbbVie$242
- Biogen$172
- Amneal Pharmaceuticals LLC$149
- Teva Pharmaceuticals USA, Inc.$148
- plus $780 from 18 others
What the payments were for
- Travel & lodging$1,03728%
- Food & beverage$2,68172%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 20 | $1,907 |
| Neurocrine Biosciences, Inc. | 9 | $320 |
| AbbVie | 4 | $242 |
| Biogen | 10 | $172 |
| Amneal Pharmaceuticals LLC | 9 | $149 |
| Teva Pharmaceuticals USA, Inc. | 2 | $148 |
| ANI Pharmaceuticals, Inc. | 6 | $106 |
| Pfizer | 4 | $93 |
| UCB, Inc. | 2 | $69 |
| Eisai Inc. | 3 | $68 |
| AstraZeneca | 4 | $61 |
| Acadia Pharmaceuticals Inc | 3 | $57 |
| Novartis | 2 | $52 |
| Genentech USA, Inc. | 3 | $48 |
| Sanofi | 2 | $43 |
| Lilly USA, LLC | 2 | $29 |
| SK Life Science, Inc. | 2 | $26 |
| MDD US Operations, LLC | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Abbott | 1 | $14 |
| Tanabe Pharma America, Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,699
- UBRELVY$125
- INGREZZA$125
- AJOVY$125
How this compares
$3,718 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlatopaGlatiramer Acetate | 11 | $29,612 |
| Paliperidone ErPaliperidone | 14 | $5,067 |
| Lacosamide | 37 | $3,052 |
| Divalproex Sodium | 74 | $2,929 |
| Oxcarbazepine | 39 | $2,736 |
| Levetiracetam | 97 | $2,726 |
| Memantine Hcl | 67 | $2,087 |
| Temazepam | 23 | $2,051 |
| Rasagiline Mesylate | 17 | $1,831 |
| Quetiapine Fumarate | 97 | $1,792 |
| Donepezil Hcl | 179 | $1,791 |
| Glycopyrrolate | 58 | $1,189 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 45 | $1,171 |
| Carbamazepine | 18 | $1,032 |
| Gabapentin | 41 | $801 |
Paid to pharmacies, not to this prescriber.
Other neurology in Antioch
- Timothy CloughesyLos Angeles$33.1M
- Jack FlorinFullerton$13M
- David KudrowSanta Monica$12.8M
- John Ravitsla Jolla$8.4M
- Perminder BhatiaFresno$8.3M
- Perry ShiehLos Angeles$8.2M
- Benjamin FrishbergCarlsbad$8.2M
- Bruce CreeSan Francisco$8M
- Lawrence RechtPalo Alto$6.6M
- Stanley PrusinerSan Francisco$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.